Cantor Fitzgerald Transfers Coverage on Evofem Biosciences Inc (EVFM) at Overweight

Cantor Fitzgerald analyst Louis Chen takes over primary coverage on Evofem Biosciences Inc (NASDAQ: EVFM) with a Overweight rating and a price target of $9.00.

The analyst comments "The market opportunity for EVFM's Amphora is underappreciated, in our view. Amphora could be: 1) a first-in-class hormone-free birth control, 2) that also improves sexual satisfaction, and 3) prevents common STIs that are on the rise, such as chlamydia, gonorrhea, among others. Therefore, we think it is a good time to take another look at the stock ahead of important catalysts, which include: potentially positive data for EVFM's AMPREVENCE Phase 2b trial in November, Amphora NDA resubmission in 4Q19, and the announcement of at least one OUS partner for Amphora before year end."

For an analyst ratings summary and ratings history on Evofem Biosciences Inc click here. For more ratings news on Evofem Biosciences Inc click here.

Shares of Evofem Biosciences Inc closed at $4.98 yesterday.

You May Also Be Interested In

• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Jumia Technologies (JMIA) PT Lowered to $11 at Cantor Fitzgerald